布地奈德福莫特罗粉吸入剂联合噻托溴铵治疗慢性阻塞性肺疾病的临床效果

Clinical Effect of Budesonide Formoterol Powder Inhalation Combined with Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease

目的:探讨布地奈德福莫特罗粉吸入剂(信必可都保)联合噻托溴铵(思力华)在慢性阻塞性肺疾病(COPD)治疗中的效果。方法:以我院呼吸科于2018年1~12月收治的100例COPD患者作为研究对象,随机分为对照组与观察组,各50例。入院后均根据临床症状给予解痉、平喘、祛痰、抗炎等对症治疗,对照组采用布地奈德福莫特罗粉吸入剂吸入治疗,观察组在对照组基础上联合噻托溴铵口服,观察6个月,对比两组第1秒用力呼气容积(FEV1)、FEV占预计值百分比(FEV1%pred)以及用力肺活量(FVC)。结果:治疗前,两组的FEV1、FEV1%pred以及FVC无明显差异,不具有统计学意义(P>0.05);治疗后,观察组的FEV1、FEV1%pred以及FVC均明显优于对照组,差异具有统计学意义(P<0.05)。结论:在COPD临床治疗中,联合应用噻托溴铵与布地奈德福莫特罗粉吸入剂能够明显改善肺功能,控制疾病发作次数与住院次数,值得推广。

Objective:To investigate the effect of budesonide formoterol powder inhalation combined with tiotropium bromide(silihua)in the treatment of chronic obstructive pulmonary disease(COPD).Methods:From January 2018 to December 2018,100 patients with COPD were randomly divided into control group(n=50)and observation group(n=50).All patients were treated with antispasmodic,antiasthma,expectorant and anti-inflammation according to clinical symptoms,while the control group was treated with budesonide formoterol inhalant.The observation group was treated with tiotropium bromide on the basis of the control group,and the observation period was 6 months.The forced breath volume(FEV1),FEV and forced vital capacity(FVC).in the first second of the two groups were compared with the predicted value(FEV1%pred)and forced vital capacity(FVC).Results:Before treatment,there was no significant difference in FEV1,FEV1%pred and FVC between the two groups(P>0.05),but the FEV1,FEV1%pred and FVC in the observation group were significantly better than those in the control group after treatment(P<0.05).Conclusion:In the clinical treatment of COPD patients,the combined use of tiotropium bromide and budesonide formoterol powder inhalation can significantly improve the lung function of patients,control the frequency of disease attacks and hospitalization times,which is worth popularizing.